Since clinical studies of CDK9 inhibitors have been somewhat disappointing partially, due in part to a lack of biomarkers of pharmacological efficacy (9), future studies should investigate whether MED1 phosphorylation can serve as a biomarker for predicting CDK9 inhibitor therapeutic response in cancers. The gene discussed is MED1; the disease is cancer.